Measuring cancer treatment response using a specific PET scan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess changes in tumor cellular redox status in patients with stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) using 18F-FSPG PET imaging. It will compare the results with standard imaging techniques like 18F-FDG PET/CT and RECIST 1.1 response metrics over a 12-week treatment period. The study will involve 32 patients, with the primary goal of determining if changes in 18F-FSPG uptake can predict treatment efficacy. Secondary objectives include characterizing the uptake and pharmacokinetics of 18F-FSPG and correlating it with clinical biomarkers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent
2. Aged 16 or above
3. Histologically confirmed HNSCC or NSCLC, who are treatment naïve and scheduled to commence standard of care treatment ((chemo)radiotherapy)
4. Willingness and ability to comply with scheduled study visits and tests
5. Confirmation of adequate function of all major organs and systems

Exclusion Criteria:

1. Pregnant or lactating women
2. Concomitant uncontrolled medical conditions
3. Participants likely to require palliative radiotherapy within the first 12 weeks of treatment
4. Prognosis less than 3 months
5. Previous anti-cancer treatment (only treatment naïve patients eligible for inclusion)

Where it's running

• Guy's and St Thomas' NHS Foundation Trust
  London, United Kingdom Recruiting

Study contacts

• Study coordinator: Gark Cook
• Email: gary.cook@kcl.ac.uk
• Phone: 0207 188 8364

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI analysis of ECGs to detect structural heart disease

  This project will test whether AI can read traditional and wearable ECGs to find undiagnosed valve disease, pulmonary hypertension, and heart failure in adults.

  Recruiting at 6 sites Imperial College London · Bristol and 5 other locations · NCT07057466

• Heart failure with preserved ejection fraction in people with COPD: clinical course and prognosis

  This project will see how often HFpEF appears in people aged 50–70 hospitalized with COPD and whether having HFpEF changes their symptoms, exercise capacity, and prognosis.

  Recruiting at 2 sites National Medical Research Center for Therapy and Preventive Medicine · Kazan' and 1 other locations · NCT07375433

• Treatment using CAR-T cells targeting B7-H3 for triple-negative breast cancer

  This study is testing a new CAR-T cell treatment aimed at a specific target for people with hard-to-treat triple-negative breast cancer to see if it is safe and how much can be given.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06347068

• Using CAR-T cells to target B7-H3 in pancreatic cancer

  This study is testing a new treatment using specially modified immune cells to see if they can safely help people with pancreatic cancer that has come back after other treatments.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06158139

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.